✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

A cisgender woman starting PrEP often asks the same first question: “Will this mess with my birth control?” The short answer is no. Tenofovir/emtricitabine (TDF/FTC) — the only PrEP regimen validated for cisgender women — does not affect the metabolism of hormonal contraceptives. The active ingredients in oral contraceptive pills, patches, vaginal rings, hormonal IUDs, injectable contraceptives, and implants all maintain their efficacy when taken with TDF/FTC. There is no pharmacokinetic interaction, no drug-drug interaction reducing either drug’s effect, and no shared metabolic pathway that creates a safety concern.

What does matter for women combining the two: both PrEP and most contraceptive methods require consistent adherence to work. The behavioral demands stack, even though the drugs don’t. And PrEP does not prevent pregnancy any more than contraception prevents HIV — the two interventions have separate purposes that should be considered separately.

PrEP and Birth Control: Do Tenofovir/Emtricitabine and Hormonal Contraceptives Interact?

Reviewed by Morgan Ellis, Clinical Pharmacy Editor — MedsBase Medical Review Team. Last updated: 16 May 2026.

Quick Answer: Is PrEP Safe with Birth Control?

Yes. Tenofovir/emtricitabine (TDF/FTC) — the PrEP regimen approved for cisgender women — does not interact with any hormonal contraceptive method. Combined oral pills, mini-pills, patches, vaginal rings, hormonal IUDs, implants, and injectable contraceptives all maintain their efficacy on PrEP. There is no metabolic interaction, no shared enzyme pathway, and no measured reduction in contraceptive effect. The two interventions address different risks — pregnancy and HIV — and should be assessed independently. Adherence to both is the only real challenge.

Why There Is No Pharmacokinetic Interaction

Drug-drug interactions usually happen through one of three mechanisms:

• Shared metabolic enzymes — most commonly the cytochrome P450 (CYP) family. If one drug induces or inhibits the enzymes that metabolise another, concentrations shift.
• Shared transporters — proteins that move drugs across cell membranes (e.g., P-glycoprotein, OATP).
• Pharmacodynamic interaction — drugs affecting the same body system additively or antagonistically (e.g., two blood thinners).

For TDF/FTC and hormonal contraceptives, none of these mechanisms produces clinically meaningful interaction:

Metabolic pathways

• TDF and FTC are predominantly renally cleared (kidney excretion), not hepatically metabolised. They do not engage the CYP system.
• Estrogens and progestins are predominantly hepatically metabolised (CYP3A4 for ethinyl estradiol, CYP3A4 / CYP2C9 for some progestins).
• Different pathways, no overlap, no interaction.

Transporter overlap

• TDF and FTC are not significant inducers or inhibitors of P-glycoprotein or OATP.
• Hormonal contraceptives have minor P-gp activity but the impact on tenofovir clearance is clinically negligible.

Direct pharmacodynamic interaction

• None. The antiretroviral mechanism (nucleoside reverse transcriptase inhibition) and the contraceptive mechanism (ovulation suppression and cervical mucus thickening) are entirely separate.

This has been confirmed through multiple pharmacokinetic substudies in the original PrEP clinical trials (Partners PrEP, FEM-PrEP, TDF2) and through dedicated drug-interaction studies. The combination is safe and effective.

By Contraceptive Method

Combined oral contraceptives (COCs)

These contain ethinyl estradiol + a progestin (norethindrone, levonorgestrel, drospirenone, desogestrel, etc.). Common brands and generics include Yasmin (drospirenone), Yaz (drospirenone, low-dose), Ovral-L (levonorgestrel), Loette (levonorgestrel low-dose), Triquilar (triphasic), and Diane 35 (cyproterone — for women with hyperandrogenism / PCOS / acne).

• PrEP interaction: none. Contraceptive efficacy maintained.
• Adherence consideration: both COCs and PrEP are daily oral medications. Co-administration is convenient — both pills at the same time of day, same routine.

For broader contraceptive selection see our birth control methods comparison, our Yasmin guide, and our Diane-35 guide.

Progestin-only pill (POP / “mini-pill”)

Norethindrone 0.35 mg or drospirenone 4 mg daily. Used by women who cannot take estrogen (breastfeeding, history of VTE, smokers over 35).

• PrEP interaction: none.
• Adherence consideration: POPs require strict timing (within 3 hours of the same time daily, for traditional formulations). The stacked adherence demand is meaningful — two daily pills with different forgiveness windows.

Hormonal IUD (Mirena, Liletta, Skyla, Kyleena)

Levonorgestrel-releasing intrauterine system. Lasts 3 to 8 years depending on the device.

• PrEP interaction: none. The IUD releases hormone locally; minimal systemic absorption.
• Adherence consideration: excellent — no daily dosing requirement. PrEP becomes the only daily-dosing demand.
• One of the best-matched contraceptive options for women on PrEP because the adherence burden is offloaded.

Copper IUD (Paragard)

Non-hormonal, lasts up to 10 to 12 years.

• PrEP interaction: none. No drug component to interact.
• Adherence consideration: ideal — long-acting, non-hormonal, no daily commitment.
• Especially suitable for women who cannot use hormonal contraception or prefer to avoid hormones.

Implant (Nexplanon)

Etonogestrel subdermal implant. Lasts 3 years.

• PrEP interaction: none.
• Adherence consideration: excellent — set-and-forget for 3 years.

Injectable contraceptive (Depo-Provera, Depo-SubQ)

Medroxyprogesterone acetate 150 mg IM or 104 mg SQ every 3 months.

• PrEP interaction: none.
• Adherence consideration: good — quarterly clinic visit rather than daily dosing for contraception. PrEP remains daily.
• Note: Depo-Provera has separate bone density considerations independent of PrEP; long-term users should be aware of cumulative BMD effects.

Vaginal ring (NuvaRing, EluRyng, Annovera)

Etonogestrel + ethinyl estradiol vaginal ring; 3 weeks in, 1 week out, OR 13 cycles for Annovera.

• PrEP interaction: none.
• Adherence consideration: good — monthly cycle rather than daily.

Transdermal patch (Xulane, Twirla)

Norelgestromin + ethinyl estradiol patch, weekly.

• PrEP interaction: none.
• Adherence consideration: good — weekly patch change.

Emergency contraception

Levonorgestrel 1.5 mg single dose (i-pill, Postpone 72) or ulipristal acetate 30 mg.

• PrEP interaction: none.
• Note: emergency contraception works for pregnancy prevention only. It does not provide HIV protection — if exposure included potential HIV risk and you are not on PrEP, consider PEP within 72 hours.

For emergency contraception guidance see our levonorgestrel emergency contraception guide.

The Behavioral Question: Adherence Stacking

The hidden challenge of combining PrEP and contraception is not pharmacological — it is behavioral. Both interventions require some level of consistent attention:

• Daily PrEP — 7 pills per week, ideally same time of day.
• Combined oral contraceptive — 21 to 28 pills per cycle, daily.
• Progestin-only pill — daily within a 3-hour window.
• NuvaRing — monthly insertion / removal.
• Patch — weekly change.
• Depo-Provera — quarterly clinic visit.
• Implant / IUD — periodic placement, otherwise hands-off.

For women on daily oral PrEP, the cleanest contraceptive companions are the long-acting reversible contraceptives (LARCs) — hormonal or copper IUD, or implant. These remove the daily adherence demand on the contraceptive side, leaving PrEP as the only daily commitment.

If both PrEP and OCP adherence is solid, the combination is fine. If one is borderline, consider whether shifting the contraceptive method to a LARC would simplify the overall regimen.

Critical Reminders for Cisgender Women on PrEP

Only TDF/FTC is approved for cisgender women

This bears repeating because it is the most common error. TAF/FTC (Descovy and Taficita) has not been validated for cisgender women’s vaginal exposure — the DISCOVER trial did not enroll enough women to establish efficacy. Cisgender women on PrEP must use TDF/FTC: Tenvir-EM, Ricovir-EM, US generic Truvada, or branded Truvada.

2-1-1 on-demand PrEP is not approved for cisgender women

The IPERGAY trial that validated 2-1-1 enrolled only cisgender MSM. Vaginal-tissue pharmacokinetics differ from colorectal-tissue pharmacokinetics; the on-demand protocol does not safely transfer. Daily dosing is required. See our on-demand PrEP 2-1-1 guide for the full discussion of who qualifies for event-driven dosing.

Pregnancy planning

TDF/FTC is generally considered safe during pregnancy with the longest safety record in pregnant women on antiretroviral therapy. For women planning pregnancy or actively pregnant who want HIV protection, TDF/FTC remains the standard PrEP regimen. Specific guidance varies by jurisdiction — discuss with a clinician familiar with HIV care in pregnancy.

Breastfeeding

TDF and FTC are detectable in breast milk but at low concentrations. The general consensus is that PrEP is compatible with breastfeeding, particularly given the value of continued HIV protection during this period. Local guidelines may vary.

STI protection

Hormonal contraceptives do not protect against STIs. PrEP protects only against HIV. For women on both, condoms remain the standard for bacterial and viral STI prevention. Doxy-PEP (doxycycline 200 mg within 72 hours of sex) is being increasingly used for bacterial STI prevention in some populations — see the PrEP Starter Pack for the combined approach.

Frequently Asked Questions

Will my birth control pill still work if I’m on PrEP?

Yes. TDF/FTC does not affect the metabolism of oral contraceptives. Both ethinyl estradiol and progestin components maintain their pharmacokinetic profile and contraceptive efficacy. Multiple clinical pharmacokinetic studies have confirmed this directly.

Can I take Yasmin (drospirenone) with Truvada?

Yes, without interaction concerns. Yasmin works at full efficacy alongside TDF/FTC. Yasmin’s diuretic-adjacent mechanism (drospirenone has antimineralocorticoid activity) does not interact with tenofovir, which is renally cleared but not affected by the drospirenone effect.

What about Diane-35 — does the cyproterone component affect PrEP?

No. Diane-35 contains cyproterone acetate + ethinyl estradiol. Neither component has a metabolic interaction with TDF or FTC. The two regimens work in entirely separate pathways.

Does PrEP reduce the effectiveness of Depo-Provera?

No. Pharmacokinetic studies in the Partners PrEP cohort and dedicated drug-interaction trials confirmed no significant effect of TDF/FTC on medroxyprogesterone acetate concentrations. Contraceptive efficacy is maintained.

I have a hormonal IUD — does PrEP affect it?

No. The IUD releases progestin locally with minimal systemic absorption; even if there were a metabolic interaction, the systemic concentrations would be too low to be clinically relevant. Hormonal IUDs (Mirena, Liletta) are fully compatible with PrEP and are often the preferred contraceptive method for women on daily PrEP because they reduce overall adherence burden.

Can I use the morning-after pill if I’m already on PrEP?

Yes. Levonorgestrel emergency contraception (Plan B, i-pill, Postpone 72) and ulipristal acetate (Ella) both work normally for women on TDF/FTC PrEP. PrEP does not protect against pregnancy, and emergency contraception does not protect against HIV.

Should I stop my birth control when I’m having my PrEP renal monitoring?

No. Routine PrEP monitoring (eGFR, urinary protein, hepatitis testing, HIV testing) is unaffected by hormonal contraceptive use. Continue both regimens through routine monitoring.

What if I’m planning pregnancy — should I stop PrEP first?

Generally no. TDF/FTC is the most studied antiretroviral regimen in pregnancy, with extensive safety data. Many women continue PrEP through preconception, pregnancy, and breastfeeding to maintain HIV protection during what is often a higher-risk period (more frequent sex with a partner who is or may become positive, immune changes during pregnancy). Discuss with your clinician.

If my partner is HIV-positive and I’m trying to conceive — does PrEP-plus-contraception planning change?

Yes, this scenario needs specific clinical planning. If the partner is on antiretroviral therapy with sustained undetectable viral load (U=U status), HIV transmission risk during natural conception is essentially zero. PrEP can be continued for layered protection during the conception window. After conception, contraception is no longer relevant; PrEP can usually be continued through pregnancy with clinician guidance.

What about doxycycline (Doxy-PEP) — does that interact with my birth control?

Doxycycline historically had concerns about reducing OCP efficacy via gut bacteria effects on enterohepatic recirculation of estrogen. The evidence for this is weak and modern guidelines do not require additional contraception with short-course doxycycline for most women. Long-term doxycycline use (e.g., chronic acne treatment) carries the same theoretical concern; clinically meaningful contraceptive failure is rare.

The Bottom Line

PrEP (TDF/FTC) and birth control work together without interaction. Every hormonal contraceptive method — pills, patches, rings, IUDs, implants, injections — and the copper IUD all maintain their full efficacy on PrEP. The pharmacokinetic concern that prompts the question simply does not exist for these drug pairs.

The real consideration is behavioral: daily PrEP plus daily OCP means two daily adherence tasks, and for some women, simplifying with a long-acting contraceptive (LARC — implant, IUD) leaves PrEP as the only daily commitment. The functional benefit is meaningful.

The biggest mistake in this space is using the wrong PrEP regimen for cisgender women — TAF/FTC and 2-1-1 are not approved for vaginal exposure. The right regimen is daily TDF/FTC, period.

For ongoing supply and product details see our verified PrEP options: Tenvir-EM, Ricovir-EM, Tavin-EM, and the PrEP Starter Pack. For contraception: Yasmin, Yaz, Ovral-L, Loette, Triquilar, Diane 35, and i-pill emergency contraception. Related reading: birth control methods comparison, Yasmin contraceptive pill guide, Diane-35 guide, levonorgestrel emergency contraception, buying PrEP online, Truvada vs Descovy, on-demand PrEP 2-1-1, and the PrEP primer.

Every order is covered by our Reshipment Assurance Policy: if your parcel does not arrive within 20 business days of dispatch (EMS or ITPS), we send a replacement at no extra cost.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.